Literature DB >> 3718817

9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures.

C A Scott, D Westmacott, M J Broadhurst, G J Thomas, M J Hall.   

Abstract

Four cell lines of human (CCRF CEM and U266BL) or murine (L1210 and P388D1) origin, resistant to the anthracycline antibiotic Adriamycin (doxorubicin) were selected in vitro from cultured cells by serial passage in the presence of Adriamycin. The resistant sublines were also cross-resistant to Mitoxantrone, 4'-epi Adriamycin and a number of novel anthracyclines including 4'-deoxy and 4'-methoxy analogues. However, a series of 9-alkyl substituted 4-demethoxyanthracyclines retained full activity against all the resistant sublines as did Aclacinomycin A. These results suggest that 9-alkyl substitution of 4-demethoxy-anthracyclines is an important determinant of activity against Adriamycin-resistant cell lines in vitro.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3718817      PMCID: PMC2001372          DOI: 10.1038/bjc.1986.101

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukemia.

Authors:  M Inaba; R K Johnson
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

Review 2.  Adriamycin. A new anticancer drug with significant clinical activity.

Authors:  R H Blum; S K Carter
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

3.  Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.

Authors:  B T Hill; L Y Dennis; X T Li; R D Whelan
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells.

Authors:  K Dano
Journal:  Biochim Biophys Acta       Date:  1973-10-25

5.  Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies.

Authors:  J L Biedler; H Riehm
Journal:  Cancer Res       Date:  1970-04       Impact factor: 12.701

6.  Acquired resistance to cancer chemotherapy.

Authors:  P Selby
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-28

7.  Mode of action of calcium antagonists which alter anthracycline resistance.

Authors:  D Kessel; C Wilberding
Journal:  Biochem Pharmacol       Date:  1984-04-01       Impact factor: 5.858

Review 8.  Tumour cell resistance to anthracyclines--a review.

Authors:  S Kaye; S Merry
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor.

Authors:  T Skovsgaard
Journal:  Cancer Res       Date:  1980-04       Impact factor: 12.701

  9 in total
  10 in total

Review 1.  Multiple drug resistance and intermediate filaments.

Authors:  A E Cress; W S Dalton
Journal:  Cancer Metastasis Rev       Date:  1996-12       Impact factor: 9.264

2.  Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A.

Authors:  H M Coley; P R Twentyman; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Toxicity of novel anthracycline derivatives towards normal myeloid bone marrow progenitor cells (CFU-GM) is not increased by verapamil.

Authors:  F W Busch; U Schmittele; G Ehninger
Journal:  Blut       Date:  1990-04

4.  Decreased resistance to N,N-dimethylated anthracyclines in multidrug-resistant Friend erythroleukemia cells.

Authors:  A Schaefer; J Westendorf; K Lingelbach; C A Schmidt; D L Mihalache; A Reymann; H Marquardt
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line.

Authors:  S P Cole
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL).

Authors:  P B Jensen; L Vindeløv; H Roed; E J Demant; M Sehested; T Skovsgaard; H H Hansen
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

7.  Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression.

Authors:  H M Coley; P Workman; P R Twentyman
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

8.  Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.

Authors:  G Lehne; P De Angelis; O P Clausen; H E Rugstad
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

9.  Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines.

Authors:  H M Coley; W B Amos; P R Twentyman; P Workman
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

10.  In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.

Authors:  E Klumper; R Pieters; M L den Boer; D R Huismans; A H Loonen; A J Veerman
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.